Enanta pharmaceuticals, inc. (ENTA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12
Cash flows from operating activities
Net income

23,665

33,815

46,383

64,612

77,864

86,274

71,956

81,044

52,330

34,383

17,710

-20,600

-13,250

-9,503

21,666

29,280

32,774

63,172

78,992

68,138

115,773

81,817

34,438

35,037

-19,154

-17,700

9,627

0

0

0

Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense

18,752

18,481

19,226

18,824

18,685

17,568

15,845

14,945

14,022

13,924

13,071

12,371

11,739

10,629

9,354

8,641

7,755

6,802

5,838

4,836

4,028

3,351

2,682

2,173

1,636

1,141

1,063

0

0

0

Depreciation and amortization expense

3,595

3,482

3,258

3,028

2,800

2,611

2,518

2,421

2,316

2,231

2,137

2,028

1,910

1,815

1,661

1,410

1,141

849

639

545

468

406

352

315

288

257

221

0

0

0

Deferred income taxes

-3,562

-1,563

-3,138

-2,448

-1,733

-1,722

1,858

9,939

6,574

2,918

-1,654

-12,080

-7,012

-4,586

-2,294

498

-1,555

-77

11,028

0

0

0

-

-

-

-

-

-

-

-

Income tax benefit from stock awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,814

0

0

0

-

-

-

-

-

-

-

-

Premium paid on marketable securities

0

0

-

-

-

-

319

686

615

906

1,229

1,228

1,209

671

518

1,109

1,587

3,044

3,042

2,241

3,150

1,746

2,002

0

0

0

-

-

-

-

Gain on sale of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities

2,502

3,689

4,336

4,086

3,158

1,900

835

100

-406

-602

-702

-771

-907

-1,137

-1,511

-1,897

-2,222

-2,335

-2,244

-2,135

-1,950

-1,956

-2,120

-2,201

-2,063

-1,693

-1,262

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Change in fair value of warrant liability and Series 1 nonconvertible preferred stock

-

-

-

-

-

-

-59

-73

-90

-105

-159

-60

-59

31

29

247

248

156

347

246

196

27

-166

-104

-56

344

381

0

0

0

Other non-cash items

-

16

-25

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Accounts receivable

-12,012

-17,316

-15,892

-12,895

-4,418

46,777

56,591

49,751

35,090

12,692

-2,227

-6,467

-4,045

-7,452

-2,448

2,254

5,923

-58,757

13,565

11,325

6,083

76,347

916

-477

329

-14,054

-241

0

0

0

Unbilled receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-433

-1,376

-1,550

-873

-2,337

-883

-54

953

1,986

1,278

836

386

-1,109

0

0

0

Prepaid expenses and other current assets

5,783

6,517

10,845

8,243

9,147

3,561

918

2,774

-1,195

-198

-5,678

-1,553

-1,541

-4,253

964

5,505

6,113

7,365

6,680

701

-903

-572

-568

-145

871

-84

307

0

0

0

Operating lease, right-of-use assets

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-1,826

1,488

1,791

1,510

3,638

1,570

1,317

-638

510

1,794

633

3,491

979

12

1,451

466

129

902

-543

257

571

-249

399

545

900

-975

115

0

0

0

Accrued expenses

-1,094

-837

5,750

4,649

4,041

4,935

1,843

3,448

1,942

959

3,443

1,057

2,750

1,698

1,858

1,328

-166

398

-227

408

144

659

-183

803

366

474

-285

0

0

0

Income taxes payable

-

-

-1,388

0

-5,380

-4,399

-7,910

0

0

0

-

-

-

-

548

724

-7,290

-11,956

1,199

0

0

0

-

-

-

-

-

-

-

-

Operating lease liabilities

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-64

-136

-7

0

0

0

Other long-term liabilities

-1,069

-23

291

715

724

812

564

348

365

144

478

501

611

653

397

817

761

717

649

-52

-147

-145

-140

-138

-143

-147

-147

0

0

0

Sale of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,210

3,218

3,218

7,258

8,421

10,412

10,412

6,390

5,453

0

0

0

Net cash provided by operating activities

38,115

53,527

71,418

91,214

92,729

55,065

29,220

58,185

49,341

53,917

52,653

-6,779

-4,095

8,961

35,809

35,560

23,469

112,276

76,673

74,116

123,431

20,440

20,179

22,608

-18,426

-4,263

10,653

0

0

0

Cash flows from investing activities
Purchase of marketable securities

449,484

547,227

549,312

467,409

465,094

357,939

293,103

244,225

199,819

232,410

251,371

228,161

259,141

231,478

192,429

191,211

145,033

222,773

196,304

168,238

209,665

96,337

98,405

101,385

94,754

112,968

115,888

0

0

0

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

156,897

126,368

108,407

83,359

89,277

96,511

91,506

75,364

47,501

36,831

41,825

0

0

0

Proceeds from maturities and sale of marketable securities

376,344

449,814

468,065

430,748

410,690

306,915

260,682

204,463

198,816

226,582

249,305

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

3,368

5,521

5,417

5,744

4,616

2,861

2,981

2,592

2,231

2,057

2,506

2,687

2,559

3,494

4,738

5,903

5,690

4,277

2,336

1,241

1,219

1,260

1,028

745

419

619

606

0

0

0

Net cash used in investing activities

-76,508

-102,934

-86,664

-42,405

-59,020

-53,885

-35,402

-42,354

-3,234

-7,885

-4,572

4,182

-34,903

-37,166

-43,663

-33,418

6,183

-100,845

-88,186

-83,071

-118,558

6,175

497

-16,354

-37,260

-70,366

-69,216

0

0

0

Cash flows from financing activities
Proceeds from exercise of stock options

8,243

7,993

6,848

7,191

9,664

6,969

6,244

6,005

3,228

1,466

1,079

347

423

913

1,026

1,107

1,047

793

726

603

748

1,060

1,054

1,137

790

583

559

0

0

0

Payments of initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,540

0

0

0

Income tax benefit from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,814

0

0

0

-

-

-

-

-

-

-

-

Payments for settlement of share-based awards

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of capital lease obligations

-

-

86

84

82

81

79

78

76

74

73

72

71

70

68

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

6,701

2,600

2,574

2,920

5,395

5,132

4,409

4,383

1,608

1,403

1,017

71

1,849

2,590

2,705

2,803

957

672

2,540

2,425

2,777

3,089

1,164

1,242

-677

58,320

56,911

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

-31,692

-46,807

-12,672

51,729

39,104

6,312

-1,773

20,214

47,715

47,435

49,098

-2,526

-37,149

-25,615

-5,149

4,945

30,609

12,103

-8,973

-6,530

7,650

29,704

21,840

7,496

-56,363

-16,309

-1,652

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for income taxes

-

-

12,672

17,299

26,160

26,080

26,088

21,965

10,449

583

1,588

4,527

7,927

7,927

12,616

9,622

23,717

45,713

40,072

0

0

0

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing information:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,526

0

0

0

Initial public offering costs included in accounts payable or accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Purchases of fixed assets included in accounts payable and accrued expenses

-1,169

-768

320

201

1,598

1,304

111

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities arising from obtaining right-of-use assets

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-